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ABSTRACT 
An assay for thrombin is presented wherein thrombin-catalyzed hydro-- 
lysis at Arg-Au-16 to release fibrinopeptide A (FPA) from fibrinogen 
is measured using high-performance liquid chromatography (HPLC). In 
this assay one thrombin unit (TU) is defined as that amount of 
thrombin that will release half of the FPA in one min from one ml of 
a solution of >90% clottable normal human fibrinogen (LO.35 u.21) at 
37'C, pH 7.4, r/2 0.15. One TU is equivalent to "d 0.1 NIH unit of 
thrombin and '7, 1 pm01 of pure human thrombin. At 37'C, pH 7.4, and 
plasma levels of fibrinoqen-yf 3 mq/ml, one TU will catalyze the 
release of 3.6 nmol FPA min . Variability in fibrinogen samples 
which produce dramatic differences in clotting time assays with the 
same sample of thrombin, produce little or no variation in the cata- 
lytic assay for TU. The assay for TU obviates the need for main- 
tenance of a thrombin reference standard. 
INTRODUCTION 
Thrornbin is most frequently assayed from measurements of its effective- 
ness in clotting fibrinogen. In this assay, the time from the initiation of 
the reaction to the formation of a clot is related to the concentration of 
active thrombin. Several discussions and descriptions of the clotting time 
assay have been published (e.g. l-6). Since the clotting time assay uses a 
natural substrate of thrombin, the assay should yield a reliable measure of 
the biological activity of a sample of thrombin. Clotting times, however, 
are functions of both thrombin-catalyzed proteolytic events and fibrinogen 
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dependent polymerization reactions. It is therefore not surprising that 
thrombin clotting times vary with the quality of fibrinogen, the age of fibrin- 
ogen solutions, as well as with the presence of inhibitors of fibrin polymeri- 
zation. This variability has made it necessary to maintain a thrombin refer- 
ence standard. The commonly used NIH unit of thrombin is defined as that 
amount of thrombin which in 15 set will clot 1 ml of fibrinogen that has been 
standardized with the thrombin reference standard. Thus, the activity of the 
thrombin sample is defined in terms of its potency relative to that of the 
thrombin reference standard rather than in terms of absolute catalytic activi- 
ty. The need for the reference standard might be obviated by use of a throm- 
bin assay based on direct measurement of its hydrolytic activity. 
Assays based on direct measurements of the catalytic activity of thrombin 
should employ a specific substrate of thrombin (e.g. fibrinogen) to reflect 
the biological activity of the sample and to minimize the effect of other hy- 
drolases which may be present in the sample of thrombin. In 1958, Jorpes et 
al. (3), proposed standardization of thrombin from measurements (at pH 9.0-&d 
GC) of the appearance of N-terminal glycine, which occurs upon thrombin- 
catalyzed cleavage at the peptide bond between Arg-Aal and Gly-Aal in fibrin- 
ogen. The feasibility of this thrombin determination was demonstrated by Mag- 
nusson (4) in 1960. The assay which involves Edman degradation of the throm- 
bin treated fibrinogen followed by separation and quantification of PTH-deriva- 
tives has not gained general acceptance. With the advent of HPLC and immune 
assays for FPA, however, it has become more facile to monitor the thrombin 
mediated proteolysis at Arg-AcilG. We present here an assay for thrombin which 
is based on measurements (using HPLC) of the rate of release of FPA which oc- 
curs in the thrombin catalyzed cleavage of fibrinogen at Arg-Acrl6. The assay 
obviates the need for a thrombin reference standard and yields a direct esti- 
mate of the proteolytic activity of thrombin at pH 7.4, 37'C, and r/2 = 0.15. 
METHODS 
Fibrinogen - The laboratory prepared fibrinogen (L) was purified from out- 
dated plasma by the method of Jakobsen and Kierulf (7), except that the fibrin- 
ogen solvent used to redissolve fibrinogen was the citrate saline solvent of 
Straughn and Wagner (8), and final dialysis was against 0.30 M NaCl. This fi- 
brinogen preparation behaved identically to the fibrinogen preparation used 
previously in this laboratory (9). Other fibrinogen samples used were from 
commercial sources. Their source and designation (in parenthesis) in this 
paper are: Sigma #F-3879, Lot #81F-9365, (S-I); Sigma #F-4129, Lot #51F-9300 
(S-II); Calbiochem #341576, Lot #201561 (C); Kabi, Grade L, Lot #30853 (K) and 
Cutter, PurengenH, Code 611-68 (Cu). Weighed amounts of these powders were 
dissolved in 0.30 M NaCl, dialyzed, centrifuged and used. IMCO fibrinogen (I) 
in 50 mM Tris-HCl, 0.10 M NaCl, pH 7.5 was a generous gift from L. Lorand of 
the Department of Biology and Molecular and Cell Biology, Northwestern Univer- 
sity, Evanston, Illinois, 60201. It was dialyzed into 0.30 M NaCl before use. 
All fibrinogen solutions were stored at -70°C prior to use. 
Thrombin - Thrombin reference standard (Lot J) was provided by the 
Bureau of Biologics, Bethesda, MD, and contained 310 NIH units per ampule. He- 
constitution was achieved either by addition of 1 ml of 0.01 M phosphate buf- 
fer, 0.14 M NaCl, pH 7.4, containing 0.5% PEG or by addition of 1 ml of stan- 
dard assay buffer (see below). John W. Fenton II, New York State Department 
of Health, generously provided the purified human thrombin (2.87 NIH units/ug) 
used in this work. The thrombin which was greater than 93% active by active 
site titration (10) was stored in 0.3 M NaCl at -7O'C. a-Thrombin accounted 
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for >99% of the thrombin in both samples. The concentration of thrombin was 
1% determined from its absorbance at 280 nm using an ET,9 of 18.3 in 0.1 ?I NaOH L ., 
and an Xr of 36,500 (11). 
Clottinq times - Clotting times were determined essentially as described 
by D.J. Baughman (S), wherein 0.2 ml of 1.58 mg/ml (clottable protein) was 
rapidly mixed with 0.1 ml of 3 NIH units/ml thrombin in a buffer system of 
0.05 M phosphate, r/2 = 0.15, pH 7.0, 25'C giving a final concentration of 
1.05 mg/ml clottable protein and 1 NIH unit/ml of thrombin. Clottable fibrino- 
gen was determined by the method of Baughman (5). An E:Ll of 15.1 and a mole- 
cular weight of 340,000 was used to calculate fibrinogen concentrations. 
Reaction kinetics - The release of FPA was measured at pH 7.4, 37"C, in 
phosphate buffered solutions as specified in the text. In the recommended 
standard assay for release of fibrinopeptides, 1 ml of 3.5 yM fibrinogen (7 PM 
Au-chains, 1.2 mg/ml) in 0.3 M NaCl was added to 10 ml of assay buffer. (The 
assay buffer was prepared by addition of a solution consisting of 0.05 M 
M2POl+, 0.1 b,j NaCl and 0.1% PEG 6000 to a solution consisting of 0.05 M 
Na2HP04 and 0.1% PEG 6000 until pH 7.40 was obtained.) A 0.9 ml aliquot of 
the fibrinogen-containing assay buffer was transferred to a microfuge tube 
for determination (see below) of the peak area or height corresponding to FPA 
at zero time, (RFPA),. Six ml of the remaining solution was then equilibrated 
at 37'C, and mixed with lo-200 ul of an appropriate dilution of thrombin solu- 
tion. Care was taken to dilute the thrombin stock solution with assay buffer 
containing PEG 6000 to prevent adsorption of thrombin on surfaces (12). Wit!?- 
in 2 min of the addition of thrombin, before formation of a visible clot, 0.9 
ml aliquots of the reaction mixture were added to six microfuge tubes which 
had been equilibrated at 37OC. To one tube, excess thrombin (e.g. 10 vl 
of 3-5 NIH units/ml) was added for determination at the end of 30 min of the 
peak area or height corresponding to total releasable FPA, (RFPA)f. The re- 
maining 5 tubes were incubated at 3J°C, and quenched after the desired incuba- 
tion times by addition of 0.1 ml of 3 M HC104. After addition of the 3 M 
HClOl+, which was also added to the zero-time and excess thrombin samples, 
water was added so that the total volume of liquid added to each sample was 
1.3 ml. After 10 min the precipitated protein was rerroved by centrifugation, 
and 1 ml of the resulting supernatant solution was injected into the HPLC sys- 
tem for determination of the area or height of the FPA peak. An automatic 
sample injector (Wisp from Waters Associates) was used to facilitate handling 
of multiple samples. If sufficient points were not obtained at C>-0.25 (see 
text) for a precise determination of TU/ml, additional values of !! were deter- 
mined with the remaining fibrinogen solution, using either other incubation 
times or another dilution of thrombin. The standard assay for TU/ml (see text) 
is independent of the absolute value of quenched assay solution injected into 
the HPLC system, provided that each determination of A is obtained from mea- 
surements of RFPA, (RFPA), and (RFPA)f which are based upon the same amount of 
fibrinogen. 
HPLC - A Varian 5000 liquid chromatograph was used for HPLC. The pep- 
tides were detected at 205 nm using a model 450 variable wave length detector 
from Waters Associates. Fibrinopeptide separation upon the 1 ml injection was 
achieved using a Waltman Particil-lo-ODS-3 (0.46 x 25 cm), Ultrasphere OPS 511 
(0.46 x 25 cm) or Spherisorb ODS-2 3u (0.46 x 10 cm) column, all equipped with 
a Waltman pre-column (0.21 x 5 cm). Various two-buffer gradient systems were 
studied for their effectiveness in peptide elution. The buffer systems were: 
from reference 6 where Buffer A is 0.083 M sodium phosphate (Fischer's HPLC 
grade H3P04) d' a lust& to pi 3.1 with NaOH pellets and Buffer B is 6 volumes of 
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Buffer A mixed with 4 volumes of CH 
I 
CN; from reference 10 where 3uffer A is 
0.025 M ammonium acetate (adjusted o pH 6.0 *with H3P04) and Buffer B is 0.05 ?! 
ammonium acetate mixed 1:l with CH3CN; and a buffer system described in a per- 
sonal communication (from Drs. Ebert and Bell of The Department of Medicine at 
The Johns Hopkins University) where Buffer A is 0.1% CF C02H 
suffer B is CH3CN. The sodium phosphate system employe ?l 
(pH 2.0) and 
for the standard assay 
used a linear gradient system which went from ~O%A, 30%B to lO%A, 90%B in 40 
min at flow rate of 1 ml/mn. The area under the FPA peak was proportional to 
the amount of FPA. Under conditions where sharp peaks were obtained (e.g., with 
the Spherisorb, ODS-2 3~ column) the peak height was also proportional to the 
amount of FPA. 
RESULTS 
Several systems have been reported recently for the quantification of the 
release of fibrinopeptides from fibrinogen using reverse phase HPLC chroma- 
tography (e.g. 9,13,14). These systems which differ with respect to the 
column used and the composition of the aqueous component of the eluent buffer, 
were evaluated for their suitability for use in a thrombin assay. The compo- 
sition of eluent buffer was found to be an important determinant of peptide 
recovery. The phosphate buffer system described here reproducibly yielded the 
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FIG. 1 
HPLC elution profile 
tides from a kinetic 
brinogen at 0.35 PM. 
of reaction mixtures 
NIH unit/ml thrombin 
times 0 and 4.0 min. 
(l'=Max) had 0.05 NIH 
quenched at 30 min. 
were those described 
of the fibrinopep- 
run using Kabi Fi- 
Aliquots (0.9 ml) 
containing 0.02 
were quenched at 
Another aliquot 
unit/ml and was 
HPLC conditions 
for the 0.083 M 
phosphate pH 3.1 system using a 3~ 
(0.46 x 10 cm) Spherisorb column. A 
peak corresponding to the void volume 
(not shown) is present in the first 5 
minutes of the profile. 
quenched assay mixtures containing 0.24 run01 fibrinogen before addition of 
thrombin (T=O), 4 min after the addition of 0.02 NIH unit of thrombin (T=4), 
and 30 min after the addition of 0.05 NIH unit of thrombin (T=Max). The 
peaks labeled Ap, FPA and FPB have been identified as phosphorylated (on Ser-3) 
FPA, FPA and FPB, by their amino acid composition. Fibrinopeptide A and B 
have been reported (9) to yield peak areas (at 205 nm in a 1 cm cell) of 0.044 
and 0.0512 absorbance units-ml/nmol, which correspond to molar absorptivities 
vo1.35, llo.2 FPA RELEASE AND THROHBIN ASSAY 115 
of 4.4 x 10 i; cm- lYy-l (FDA) and 5.12 x lo4 cm-IM-l (FP3). 
The thrombir-catalyzed release of FPA from fibrinogen has also been 
shown (15) to follow simple Michaelis-Menten kinetics. At pH 7.4, 37'=C, r/2 = 
0.15, Km for the release of FPA is 7.2 I.M based on the concentration of Aa- 
chains. When the concentration of Au-chains is less than 0.1-K, the Michaelis- 
Mencen eauation for FPA release 
d[FPA] d[Ae] = kcat [Throm] pzz 




d[FPA] d[Aal = ___ = -- 
dt dt 
* [Acr] [Throm] 
Integration of equation 2 yields 





Thus a plot of ln([Aa]/[Ac]o) versus time should be linear with a slope pro- 
[Acr] are the concen- 
. The ratio 
portional to the thrombin concentration, where [Aal, and 
trations of intact Acc-chains at t=O and t=t, respectively 
[Acr]/[Acc], may be evaluated from the equation 
(Aal p= [FPA]f - [FPA] = (RFPA)f - (WPA] 
LAolo [FPAlf - @PAlo (RFPA)f - (P.='A]o 
= 0 (4) 
where RFPA is the area or height of the FPA peak and the subscripts o, and 
f denote values before the addition of thrombin and after sufficient incuba- 
tion with thrombin so as to release all of the FPA. Peak height rather than 
area could be used for RE'PA when the chromatogram yielded sharp peaks whose 
height was proportional to the amount of FPA. 
A time dependence for the release of FPA is shown in Fig 2A for three sam- 
ples of fibrinogen. The plot in Fig 23 illustrates the expected linear depen- 
dence of ln([Aa]/[Aa]o) obtained for the fibrinogen samples. Substitution of 
[AcxI/[AcxI~ = 0.5 at tO_S (one half-life for Aa-chains) in equation 3 yields 
1 kcat -=- [Throm] (5) 
to.5 Kmln2 
Since l/toes is proportional to the thrombin concentration, it may be used to 
specify thrombin content. If a thrombin unit (TU) is defined as that amount 
of human thrombin which will release half the FPA in one min from 1 ml of 90% 
clottable human fibrinogen (50.35 JIMI at 37'C, pH 7.4, r/2 = 0.15; l/to S is 
equivalent to the concentration of thrombin units (TU/ml) in the assay mixture. 
Inspection of equatioml-5 reveals that thrombin units can be determined 
from measurements of peak areas or height without knowledge of the absolute 
concentration of functional fibrinogen as long as the fibrinogen concentration 
is SO.35 u# (i.e. LO.70 PM Aa-chains). The dashed lines in Fig 23 illustrate 
a graphical determination of to S. Since the y- intercept of the line of Fig 
23 should be one, the concentration of thrombin units may be determined from 
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the value of SF?A at a single time (preferably a time +a: gi.Jes a l-:;aL>.:e 
close to 0.5) using a fibrinogen solution with a previously determined v;al~;e __ 
of (RFPAJo and (P.FPA\)f. Precise values of TU, however, are best determined 
using more than one value of i?. It is also important to periodically reevaiu- 
ate (RFPAjo and (PFPA)f, since variations in flow rate, injection volume and 
fibrinogen concentration in the sample will cause the absolute values of 
(RFPA),, (RFPA)f and (RFPA) to change. 
TIME (MINI 
FIG. 2 
2 4 6 8 IO 12 
TIME (MINI 
Thrombin-mediated release of FPA from different samples of 0.35 UM fibrinogen 
(~),a; (K),a ; and S-I,A ; at 10 mM phosphate, pH 7.4, 37'C, r/2 = 0.15, 
0.02 NIH unit/ml thrombin. The plot in Fig 2A depicts the time course of the 
appearance of FPA, and that in Fig 2B depicts the first order decay of intact 
Au-chains. 
0.146 min-' 
The solid lines were calculated using equation 3 and a value of 
for kcat [Throml/Km which gave the best fit of the data to equa- 
tion 3. 
Thrombin units may also be estimated from equation 6. 
TU/ml = l/to.5 = _ln (mPA)f - (RFPA) /t*ln2 = -(ln A)/tmln2 (6) 
(RFPAjf - (RFPA) 
0 
Values of TU obtained by averaging several values of TU, estimated from mea- 
surements of A at times 5 2t0 5, should yield the most reliable estimates of 
TU. Values of A at t > 2t0 5'should be avoided, however, since small errors 
in the determination of P,FPA for these points can result in large relative 
errors in TU. 
The data in Table I illustrate that the determination of TU is essentially 
independent of the fibrinogen sample used. Seven different samples of fibrino- 
gen with clottabilities ranging from 79% - 96% exhibited 0.21 ? 0.01 TU when 
assayed with 0.02 NIH unit of thrombin having a specific activity of 2.87 NIH 
unitlug. The variation between the highest and lowest determination of TU was 
17%, whereas the corresponding variation for thrombin clotting times (deter- 
mined with 1 NIH unit/ml of thrombin) was 140%. 
Under the conditions used for the assay, the release of FPA is followed 
by end to end polymerization which in turn is followed by the release of FPB 
(15). It is therefore not surprising that the release of FPA is not affected 
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T.ABLE I 




TU/ml % Clottable Clotting Time 
(Sac) 
L 0.209 96 39 
S-I 0.209 94 46 
S-II 0.224 79 34 
C 0.209 91 43 
I 0.212 89 54 
cu 0.191 89 22 
K 0.208 94 34 
aTU/ml was evaluated with 0.32 uM fibrinogen in 10 m&l phosphate which was 
mixed under the assay conditions with 0.02 NIH unit of thrombin/ml. Clotting 
times were determined at 1 NIH unit/ml of thrombin. 
by the presence of polymerization inhibitors such as Gly-Pro-Arg-Pro and EDTA 
(Fig 3). These inhibitors, however, drastically prolong the clotting times 
and inhibit the release of FPB (15). In addition to being insensitive to the 
presence of polymerization inhibitors the determination of thrombin units was 
unaffected by the presence of 1mM Ca+2. The assays described up to this point 
in the text were carried out in the presence of a low concentration of phos- 
phate buffer (10 mM) to approximate plasma concentrations of phosphate and 
TIME (MIN) 
FIG. 3 
Effect of EDTA and Gly-Pro-Arg-Pro on the release of FPA from fibrinogen 
(0.32 - 0.34 uM) by thrombin (0.030 NIH unit/urn11 in 10 mM phosphate at pH 7.4, 
37'C, r/2 = 0.15, 0.001% PEG. 
A, 25 mu EDTA. Of 
no additions; izl, 0.54 mM Gly-Pro-Arg-Pro; 
minimize precipitation which occurs when Ca+2 is added to a more concentrated 
phosphate buffer. To minimize the possibility of inadvertent alterations in 
pH a more concentrated phosphate buffer (0.05 M) is suggested for the standard 
assay. Fig 4 illustrates determination of TU concentration for four different 
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concentrations of a freshly reconstituted ttromb:n referer.ce standard. The 
slope of the 21ot in Zig 43 indicates that in the recomexded standard assal? 
1 TU is equivalent to 0.118 NIH unit. The estimate that 3.09 I c.56 ?:IH unit 
(11) is equivalent to 1 "g of pure human thrombin together with the observatioz 
that 1 TJ is equivalent to 0.118 NIH unit indicates that 1 TU is equi,ialent to 
1.05 t 0.19 pm01 of pure human tnrombin (ML. = 36,500). 
TIME (MINI 
FIG. 4 
Relationship between thrombin-units and NIH units. The recommended standard 
assay described under "Methods" was used wherein 10 ~1 co), 25 ul (m), 50 ~1 
(A) and 100 ~1 (0) of a stock solution of thrombin NIH reference standard 
containing 2.55 NIH units/ml was added to 6 ml aliquots of 0.32 uM fibrinogen 
in assay buffer to yield 0.00424, 0.0106, 0.0211, 0.0418 NIH unit/ml thrombin. 
The values of TU/ml (l/tO.5) determined from plots in Fig 4A are plotted in Fig 
4B against the corresponding values of NIH/ml in the assay buffer. 
THROMBIN (NIH U/ML) 
DISCUSSION 
The standard assay for thrombin units described under "Methods" is based 
upon the proteolytic activity of thrombin toward one of its natural substrates 
under conditions of pH, temperature, and ionic strength close to those used in 
many biological applications of thrombin. The assay which is based upon throm- 
bin catalyzed release of FPA is insensitive to the presence of polymerization 
inhibitors. It should also be unaffected by variations in fibrinogen structure 
spatially remote from the scissile bond. Winen normal human fibrinogen with a 
clottability ? 90% is used, no significant dependence of the assay on the fi- 
brinogen is detected. Thus, the assay does not require a thrombin reference 
standard for calibration. Another advantage of the assay is that the thrombi 
unit specifies the catalytic potency of thrombin samples in molecular terms- 
Additionally, rearrangement of equation 6 yields the relationship 
[TU]*KM*ln 2 = kcat [Throm] ( 
n 
7) 
where [TU] represents the concentration of thrombin units (TU/ml). Since KM = 
7.2 uM under the assay conditions (15), 
5.0 [TU] = kcat [Throml (8) 
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slhstitu-cio?. of equation 9 in equation 1 yields equation 9 





which predicts the rate of release of FPA in pM-min -1 as a function of the u 
molar concentration of Act-chains o f fibrinogen and the concentration of throm- 
bin. At a plasma concentration of fibrinogen of 3 mg/ml (17.6 T.IM AZ-chains), 
one TU shoilld catalyze the release of 3.6 nmol FPA/min at 37'C, pH 7.4. 
The assay presented here differs from most determinations of enzyme acti- 
vity in that it relies on the determination o f half--lives for the first-order 
decay of substrate rather than the determination of initial velocities for 
substrate decomposition. Reproducible determination of initial velocities 
usually requires duplication of functional substrate concentrations. This 
could be problematical when different samples of fibrinogen are used. Half- 
lives for the first order release of FPA, however, should be independent of 
the initial substrate concentration, as long as [Aa] 2 O.l*Km. It is realized 
that the dependence of an initial velocity assay on variations in substrate 
concentration could be reduced by use of an initial substrate concentration 
which is substantially greater than Km. It was not considered advisable, 
however, to design an assay with a high fibrinogen concentration, since the 
presence of compet itive inhibitors (e.g. fibrinogen degradation products) 
which might be associated with certain fibrinogen samples could result in 
variations in initial velocity. That is, at a near saturating substrate con- 
centration only a small fraction of the thrombin will be free, and the throm- 
bin will be distributed between substrate and inhibitor according to their 
relative concentration and affinity for thrombin. At the low concentrations 
of fibrinogen specified for the assay presented in this work, less than 10% @f 
the thrombin is Saturated by fibrinogen. Under such conditions, contaminating 
competitive inhibitors are not likely to result in displacement of fibrinogen 
from thrombin. 
It is important to note that in some chromatographic systems the phos- 
phorylated FPA is not resolved from FPA. The time dependence of the release 
of these two peptides do not differ significantly at the low fibrinogen con- 
centration used for the assay. Thus, thrombin units can be accurately deter- 
mined from measurements of the areas or heights of peaks resulting from the 
combined presence of both peptides. 
It is conceivable that certain laboratories will find it more convenient 
to continue to determine thrombin units from clotting times using a thrombin 
reference standard. The methods presented here, however, should also facili- 
tate this approach by providing the means for direct measurement of the cata- 
lytic potency of the thronibin standard needed to calibrate the fibrinogen. 
Additionally, the observation that there are 8.5 TU/NIH unit establishes a 
relationship between the proteolytic activity and the clotting-time assay for 
human thrombin. 
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